HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elwyn Loh Selected Research

rilotumumab

6/2015Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer.
8/2014Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.
8/2014Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
1/2014Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients.
1/2013Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
4/2011A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Elwyn Loh Research Topics

Disease

5Neoplasms (Cancer)
06/2015 - 09/2012
2Stomach Neoplasms (Stomach Cancer)
06/2015 - 01/2014
2Neutropenia
08/2014 - 03/2013
2Adenocarcinoma
08/2014 - 08/2013
1Colorectal Neoplasms (Colorectal Cancer)
08/2014
1Neoplasm Metastasis (Metastasis)
08/2014
1Venous Thrombosis (Deep-Vein Thrombosis)
08/2014
1Thrombocytopenia (Thrombopenia)
08/2014
1Venous Thromboembolism
08/2014
1Body Weight (Weight, Body)
01/2014
1Pancreatic Neoplasms (Pancreatic Cancer)
10/2013
1Breast Neoplasms (Breast Cancer)
03/2013
1Prostatic Neoplasms (Prostate Cancer)
01/2013
1Edema (Dropsy)
01/2013
1Glioblastoma (Glioblastoma Multiforme)
04/2011
1Gliosarcoma
04/2011
1Head and Neck Neoplasms (Head and Neck Cancer)
03/2007
1Rupture
03/2007

Drug/Important Bio-Agent (IBA)

7Monoclonal AntibodiesIBA
08/2014 - 04/2011
6rilotumumabIBA
06/2015 - 04/2011
5ganitumabIBA
08/2014 - 09/2012
4Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
08/2014 - 04/2011
3Cisplatin (Platino)FDA LinkGeneric
06/2015 - 03/2007
3Biomarkers (Surrogate Marker)IBA
08/2014 - 01/2013
2Epirubicin (Ellence)FDA LinkGeneric
06/2015 - 08/2014
2Capecitabine (Xeloda)FDA Link
06/2015 - 08/2014
2GemcitabineFDA Link
10/2013 - 08/2013
1Panitumumab (Vectibix)FDA Link
08/2014
1ErbB Receptors (EGF Receptor)IBA
08/2014
1Immunoglobulins (Immunoglobulin)IBA
01/2014
1AlbuminsIBA
10/2013
1Insulin (Novolin)FDA Link
10/2013
1CreatinineIBA
10/2013
1IGF Type 1 Receptor (IGF 1 Receptor)IBA
08/2013
1Insulin-Like PeptidesIBA
08/2013
1exemestane (Aromasin)FDA Link
03/2013
1Fulvestrant (Faslodex)FDA Link
03/2013
1Hormones (Hormone)IBA
03/2013
1Mitoxantrone (Novantrone)FDA LinkGeneric
01/2013
1Prednisone (Sone)FDA LinkGeneric
01/2013
1Somatomedin Receptors (Somatomedin Receptor)IBA
09/2012
1Tirapazamine (SR 4233)IBA
03/2007

Therapy/Procedure

3Therapeutics
08/2014 - 03/2007
1Castration
01/2013
1Re-Irradiation
03/2007
1Drug Therapy (Chemotherapy)
03/2007